Author

Anuradha Pandit

University of MinnesotaORCID 0000-0002-7633-1178Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Luke H. HoeppneriD· 2 shared Sk. Kayum AlamiD· 2 shared Brittney ThieleiD· 1 shared Charles M. RudiniD· 1 shared Li WangiD· 1 shared Li WangiD· 1 shared Marie Christine Aubry· 1 shared Parvathy ManojiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Luke H. HoeppnerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 5, 2026

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer

Li Wang, Anuradha Pandit, Sk. Kayum Alam…·Luke H. Hoeppner

This study shows that primary cilia formation contributes to resistance to osimertinib in EGFR-mutated NSCLC by promoting sodium influx and HDAC6 inactivity, and that targeting ciliogenesis can reverse resistance.

DOI 10.64898/2026.03.03.709408

humanproteomics

𝕏 PostBluesky

Cancer BiologyCell Death and DiseasePeer-reviewedMay 9, 2025

Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

Sk. Kayum Alam, Anuradha Pandit, Li Wang…·Luke H. Hoeppner

This study shows that dopamine D2 receptor agonists reduce angiogenesis and inhibit chemotherapy-refractory small cell lung cancer progression by targeting tumour-associated endothelial cells.

17 citationstop 4%

humanexperimental assay

𝕏 PostBluesky